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Abstract 
Background: HIV‑infected individuals on antiretroviral therapy (ART) require treatment with artemisinin‑based 
combination therapy (ACT) when infected with malaria. Artemether–lumefantrine (AL) is the most commonly used 
ACT for treatment of falciparum malaria in Africa but there is limited evidence on the safety and efficacy of AL in HIV‑
infected individuals on ART, among whom drug–drug interactions are expected. Day‑42 adequate clinical and para‑
sitological response (ACPR) and incidence of adverse events was assessed in HIV‑infected individuals on efavirenz‑
based ART with uncomplicated falciparum malaria treated with AL.
Methods: A prospective, open label, non‑randomized, interventional clinical trial was conducted at St Paul’s Hospital 
in northern Zambia, involving 152 patients aged 15–65 years with uncomplicated falciparum malaria, who were on 
efavirenz‑based ART. They received a 3‑day directly observed standard treatment of AL and were followed up until 
day 63. Day‑42 polymerase chain reaction (PCR)‑corrected ACPRs (95% confidence interval [CI]) were calculated for 
the intention‑to‑treat population.
Results: Enrolled patients had a baseline geometric mean (95% CI) parasite density of 1108 (841–1463) parasites/
µL; 16.4% (25/152) of the participants had a recurrent malaria episode by day 42. However, PCR data was available for 
17 out of the 25 patients who had malaria recurrence. Among all the 17 patients, PCR findings demonstrated malaria 
re‑infection, making the PCR‑adjusted day‑42 ACPR 100% in the 144 patients who could be evaluated. Even when 
eight patients with missing PCR data were considered very conservatively as failures, the day‑42 ACPR was over 94%. 
None of the participants, disease or treatment characteristics, including day‑7 lumefantrine concentrations, predicted 
the risk of malaria recurrence by day 42. AL was well tolerated following administration. There were only two cases 
© The Author(s) 2019. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creat iveco mmons .org/licen ses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creat iveco mmons .org/
publi cdoma in/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Open Access
Malaria Journal
*Correspondence:  cgbanda@mlw.mw; vmwapasa@medcol.mw 
†Clifford G. Banda and Mike Chaponda contributed equally to this 
manuscript
1 University of Malawi, College of Medicine, Blantyre, Malawi
2 Malawi Liverpool Wellcome Trust Clinical Research Programme, Blantyre, 
Malawi
Full list of author information is available at the end of the article
Page 2 of 11Banda et al. Malar J          (2019) 18:180 
Background
Malaria and human immunodeficiency virus (HIV) 
infections co-exist in most parts of sub-Saharan Africa 
[1]. In these settings, antiretroviral therapy (ART) naïve 
HIV-infected (HIV+) individuals are more susceptible 
to falciparum malaria infection than HIV-negative indi-
viduals [2, 3]. The World Health Organization (WHO) 
recommends the use of artemisinin-based combination 
therapy (ACT) to treat falciparum malaria infections 
[4]. Artemether–lumefantrine (AL) is one of the most 
commonly used ACT in sub-Saharan Africa and is often 
co-administered with ART in malaria-HIV co-infected 
individuals.
First-line ART regimens in many parts of sub-Saharan 
Africa contain non-nucleoside reverse transcriptase 
inhibitors such as efavirenz. Efavirenz is metabolized by 
cytochrome (CYP) 450 enzymes, particularly CYP2B6 
and to a lesser extent CYP3A4, which also metabolizes 
artemisinin-derivatives and lumefantrine, the longer-
acting partner drug of AL [5, 6]. In addition, efavirenz 
auto induces its own metabolism [7] which may lower its 
plasma concentration and that of other CYP3A4 enzyme 
substrates, such as AL. Genetic variations in these 
enzymes are therefore likely to result in different levels 
of drug–drug interactions between AL and efavirenz. In 
pharmacokinetic studies, co-administration of efavirenz 
has been shown to be associated with lower lumefantrine 
exposure (nearly 50% reduction) than when administered 
alone [8–10]. In non-pregnant adults and children, lower 
lumefantrine concentrations have been associated with 
increased risk of recurrent malaria infections [11–14]. 
However, few studies have used the WHO-recommended 
protocol [15] to evaluate the efficacy of AL in HIV+ indi-
viduals on ART suffering from uncomplicated malaria. 
Hence, there are gaps in the evidence base that inform 
malaria treatment guidelines for HIV-infected individu-
als who are on ART.
A prospective, open label, non-randomized, interven-
tional clinical trial was conducted to estimate the day-42 
polymerase chain reaction (PCR)-corrected, adequate 
clinical and parasitological response (ACPR) and inci-
dence of adverse events in HIV+ adult patients with 
parasitologically confirmed, uncomplicated clinical falci-
parum malaria who were on efavirenz-based ART. Addi-
tionally, factors associated with malaria recurrence by 
day 42 of follow up, including day-7 plasma lumefantrine 
concentrations, were also assessed.
Methods
Study site and study population
The study was conducted from October 2014 to June 
2015 at St Paul’s Hospital in Nchelenge district in the 
northern province of Zambia, which borders the Demo-
cratic Republic of Congo. The district had an estimated 
population of 147,127 according to the 2010 population 
census [16]. This is a setting of moderate-high transmis-
sion of malaria [17] and high HIV prevalence of 12.0% 
[18].
During the study period, the criteria for initiating ART 
in Zambia was WHO HIV disease stages 3 or 4, CD4 cell 
count < 350, pregnancy or lactation. First-line ART regi-
men comprised of tenofovir/lamivudine/efavirenz. AL 
was the first-line treatment for uncomplicated malaria.
Study design and clinical procedures
This was a single arm interventional study (registra-
tion number: PACTR201311000659400). HIV-infected 
patients who had been on 600 mg efavirenz-based ART 
for at least 24 weeks and were suspected to have malaria 
were pre-screened through history taking and clinical 
examination to determine their eligibility for the study. 
The study inclusion criteria were as follows: age ≥ 15 
to ≤ 65  years; weight ≥ 35  kg; documented fever (axil-
lary ≥ 37.5 °C) or history of fever 24 h prior to enrolment; 
smear positive pf malaria mono-infection with asexual 
malaria parasite densities < 200,000/µL; ability to swallow 
oral medications and willingness and ability to comply 
with scheduled visits, supervised treatment administra-
tion, laboratory tests, and other study procedures. The 
following were the exclusion criteria: severe malaria as 
of grade 3 neutropaenia and one serious adverse event of lobar pneumonia, none of which was judged as probably 
related to intake of AL.
Conclusions: AL was well tolerated and efficacious in treating uncomplicated falciparum malaria in HIV co‑infected 
adults on efavirenz‑based ART. However, a higher than anticipated proportion of participants experienced malaria 
re‑infection, which highlights the need for additional malaria prevention measures in this sub‑population after treat‑
ment with AL.
Trial registration Pan African Clinical Trials Registry (PACTR): PACTR201311000659400. Registered on 4 October 2013. 
https ://pactr .samrc .ac.za/Searc h.aspx
Keywords: Human immunodeficiency virus, Anti‑retroviral drugs, Artemether–lumefantrine, Malaria, Drug–drug 
interactions
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per WHO criteria [19]; mixed infection with another 
Plasmodium species; haemoglobin (Hb) concentra-
tion < 7  g/dL; severe sickle cell disease or sickle-haemo-
globin C anaemia; evidence of pregnancy or lactation; use 
of any anti-malarial treatment or drug with anti-malarial 
activity within the past 1  month, except cotrimoxazole; 
history of AL hypersensitivity reactions; gastrointestinal 
diseases that could alter gut absorption or motility; his-
tory of splenectomy; history of epilepsy or convulsions; 
pre-existing clinically-significant cardiac, liver, renal, 
neurological or psychiatric abnormalities; alternative 
clinical cause of fever other than malaria and participa-
tion in any investigational drug study in the past 30 days.
Finger-prick blood samples were taken from those who 
satisfied the preliminary eligibility criteria and tested for 
malaria using rapid diagnostic test (RDT) (SD BIOLINE 
Malaria Ag P.f/Pan test produced by Alere) and for hae-
moglobin concentration using Hemocue Haemoglobi-
nometer. Thick blood smear microscopy examinations 
were performed on patients with RDT-positive malaria. 
Clinical examinations were performed in those with con-
firmed malaria parasitaemia. Consenting participants 
were enrolled and scheduled for a 3-day hospital admis-
sion (treatment period) and then followed up until day 
63.
Enrolled study participants received a directly 
observed, standard 3-day course of AL  (Coartem®, 
Novartis) administered twice a day with milk as fol-
lows: 4 tablets of AL, each containing 20 mg/120 mg of 
artemether/lumefantrine administered at 0 h (treatment 
day 0), 8 (± 4) h after the first dose, then at 24 (± 4) and 
36 (± 4) h after dose (treatment day 1) as well as 48 (± 4) 
and 60 (± 4)  h after the first dose (treatment day 2). A 
repeat dose of AL was administered to participants who 
vomited within 30 min. Participants with persistent vom-
iting were withdrawn from the study and referred appro-
priately. Paracetamol ≤ 1 g was given concomitantly with 
the first dose of AL to relieve malaria symptoms. The par-
acetamol doses were repeated at intervals of 6 h, if clini-
cally indicated. Participants’ vital signs were measured at 
6-hourly intervals and adverse events were monitored. A 
12-Lead electrocardiogram (ECG) was performed before 
the first dose of AL and within 2 h after administration 
of the third dose AL. Any patient with Fridericia cor-
rected QT (QTcF) interval of ≥ 450 ms or QTc increase 
of > 60 ms from the baseline underwent follow-up ECGs 
until resolution of the abnormality. Participants were 
discharged at least 24 h after taking the third (last) dose 
of AL (post-treatment day 3) and advised to come for 
follow-up visits on post-treatment days 7 (± 1), 14 (± 1), 
21 (± 2), 28 (± 2), 35 (± 2), 42 (± 2) and 63 (± 2). Partici-
pants were encouraged to return to the health facility any 
time they felt unwell (unscheduled visits). All adverse 
events were graded using the DAIDS criteria [20]. 
Adverse events with onset or increased severity after 
the first dose of AL were counted as treatment-emergent 
adverse events (TEAEs). During follow-up visits, par-
ticipants’ time and any incurred expenses when attend-
ing the study clinic were appropriately compensated, as 
approved by the ethics committees.
Laboratory procedures
During the admission period, thick blood slides were 
collected pre-dosing and at 6-hourly intervals until after 
obtaining two consecutive malaria negative smears. The 
slides were also collected at scheduled and unscheduled 
follow-up visits. The slides were Giemsa-stained and read 
by an experienced microscopist using standard proto-
cols [21]. For quality control, all slides were re-read by 
a second microscopist; a third microscopist settled any 
discrepant readings. Dry blood spot (DBS) samples were 
collected on filter paper (Whatman  3MM®) at baseline 
and during recurrent malaria episodes. Parasite DNA 
was extracted from the DBS samples, amplified using 
polymerase chain reaction (PCR) and genotyped for 
merozoite specific protein (MSP) 1 and 2 to distinguish 
malaria recrudescence from re-infection, using methods 
previously described [22]. Samples that did not produce 
results were classified as indeterminate.
Venous blood samples were collected on days 0, 3, 28, 
42, and 63 for biochemistry tests using a Beckman  CX5® 
Chemistry analyzer, on days 0, 3, 7, 28, 42, and 63 for 
haematological tests using a Beckman  Coulter® HMX 
Analyzer and on days 0, 28 and 63 for CD4 cell count 
measurement using a BD FACSCount™ machine. Plasma 
samples collected on days 0, 28 and 63 were stored for 
future HIV viral load assays. Additionally, sparse plasma 
samples were collected to quantify lumefantrine concen-
tration during the follow-up period, these findings will be 
reported elsewhere.
On day 7, blood samples for lumefantrine PK assays 
were collected in heparin tubes. Immediately after col-
lection, the blood samples were spun in a refrigerated 
centrifuge, and the separated plasma samples were tem-
porarily frozen in liquid nitrogen before being transferred 
to a − 80  °C freezer until PK analyses. The plasma sam-
ples were analysed for lumefantrine levels at the Malawi-
Liverpool-Wellcome Trust Clinical Research Programme 
in Blantyre, Malawi, using a validated high-performance 
liquid chromatography (HPLC)-UV assay adopted and 
transferred to Malawi from the Liverpool School of 
Tropical Medicine. The PK laboratory in Blantyre par-
ticipated in WorldWide Antimalarial Resistance Net-
work (WWARN) external quality assurance programme 
[23]. Briefly, lumefantrine and the internal standard (IS) 
(halofantrine) were recovered from plasma using a single 
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protein precipitation step with acetonitrile and acetic 
acid (99:1). The supernatant was then evaporated to dry-
ness in a vacuum concentrator at 25 °C. The dried extract 
was redissolved in the reconstitution solvent metha-
nol-0.01  M hydrochloric acid (70:30), and 75  μL was 
injected into the chromatograph (Agilent 1100). Quanti-
tation of the drugs was achieved by reverse-phase HPLC. 
The optimum detection wavelength for each drug was 
335 nm. The lower limit of quantification (LLOQ) of the 
HPLC–UV assay was 50  ng/mL for lumefantrine, with 
a percent coefficient of variation of < 10. An extracted 
plasma pharmacokinetic sample from a participant was 
run in a batch comprising. Each batch run included a 
blank plasma extract, two sets of 8-concentration-level 
calibration standards, and quality controls (QCs) at three 
concentration levels: low, medium and high (0.05, 10 and 
15  μg/mL). For the batch assay to pass, the measured 
concentrations of at least 67% of the QC samples had to 
be within ± 20% of their nominal value, and at least one 
QC had to be acceptable at the LLOQ. The mean interas-
say precision values for low, medium, and high QCs were 
6.6, 8.8 and 9.2%, respectively. In addition, 75% of each 
calibration curve’s concentrations had to lie within ± 20 
and ± 15% of the nominal concentration at the LLOQ or 
all other concentrations, respectively.
Study endpoints
The primary study endpoint was proportion of patients 
with PCR-corrected day-42 ACPR, defined as patients 
who at day 42 did not have parasitaemia with identical 
falciparum malaria PCR markers (merozoite specific pro-
tein 1 and 2) to baseline, irrespective of axillary tempera-
ture, and who had not previously met any of the criteria 
of early treatment failure (ETF), late clinical failure (LCF) 
or late parasitological failure (LPF). Standard WHO defi-
nitions of ETF and LCF were used [15].
The other primary study endpoints were grade 3 or 4 
TEAEs including cases of Fridericia corrected QT (QTcF) 
interval prolongation [24] and serious adverse events 
(SAEs) as per standard definitions [25]. Local study phy-
sicians determined the relationships between AL and 
the adverse events (AEs). A Data Safety and Monitoring 
Board (DSMB) reviewed the AEs and assessed the valid-
ity of study physicians’ decisions.
Secondary efficacy endpoints included PCR-uncor-
rected day-42 ACPR, time for parasite to decline by 50% 
 (PC50) and 90%  (PC90), fever clearance time, and day-7 
lumefantrine concentrations in relation to day-42 ACPR. 
Additional exploratory analyses focused on identifying 
any potential predictors of not achieving ACPR (recru-
descence) or acquiring re-infection by day 42. Secondary 
safety endpoints were trends in haemoglobin concentra-
tions and CD4 cell counts from baseline to day 28.
Sample size
Sample size calculation was based on estimates of total 
treatment failure rate (TTFR). The 42-day PCR-corrected 
TTFR was estimated to be ≤ 10% [26]. A precision of 5%, 
around this point estimate, which resulted in the upper 
limit of the 95% Wald binomial confidence interval to be 
15%, was allowed. Using the formula for estimating a sin-
gle study population sample size [27], the effective sam-
ple size was estimated at 138. The final sample size was 
163, after adjusting for an anticipated loss-to-follow-up 
rate of 15%. Sample size calculations and subsequent sta-
tistical analyses were performed in STATA 13.1.
Statistical analyses
For the primary endpoint, three analysis populations 
were used. Firstly, the intention-to-treat (ITT) popu-
lation included patients who received at least 1 dose of 
study medication. Secondly, the per-protocol (PP) popu-
lation included all participants who received a full course 
of AL, had data available for the primary endpoint at 
day 42, and who adhered to the follow-up visit sched-
ule. Thirdly, the safety population included all patients 
who received any amount of study medication and had 
at least 1 assessment after dosing. ACPR plus 95% CI 
in PP and ITT populations were reported. The primary 
analyses was based on the ITT population while the PP 
populations assessed the robustness of assumptions that 
are made in the ITT approach. In the ITT approach, sec-
ondary sensitivity analyses were performed by firstly con-
sidering all participants with missing PCR data at day 42 
as having parasitological failure and then considering the 
same participants as having treatment success.
Statistical analyses for secondary ACPR endpoints 
were similar to the primary endpoints. In addition, 
Kaplan–Meier (KM) survival plots were used to summa-
rize the time to PCR-corrected and uncorrected treat-
ment failure in the ITT population. Parameters assessing 
post-treatment parasite clearance  (PC50 and  PC90) were 
estimated using the WWARN parasite clearance estima-
tor (WWARN PCE), as described elsewhere [28].
Descriptive statistics were computed for baseline 
variables. Wilcoxon rank-sum/Mann–Whitney U test 
was used to compare distributions of the day-7 lume-
fantrine concentrations in those who had and did not 
have malaria recurrence by day 42. Lumefantrine con-
centrations below the lower limit of quantification 
(< 50  ng/mL) were imputed to half the lower limit of 
quantification (25  ng/mL). Additionally, Wilcoxon 
matched paired signed-rank test was used to compare 
baseline and day-28 CD4 cell and haemoglobin val-
ues. Cox univariate and multivariate regression models 
were used to determine potential predictors of malaria 
recurrence by day 42 and to compute hazard ratios in 
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the ITT population. In the univariate analysis, potential 
predictors such as age, gender, baseline CD4 cell count, 
malaria parasite density were determined as significant 
if they had a p-value of < 0.05. Significant variables in 
the univariate models were then fitted in a multivariate 
model and covariates that had a p-value of < 0.05 in the 
multivariable model were considered independent pre-
dictors of malaria recurrence.
Results
Study profile
As shown in Fig.  1, 456 patients presenting with symp-
toms suggestive of malaria at St Paul’s Hospital were 
screened for trial eligibility. Of these, 152 with positive 
falciparum malaria blood met the eligibility criteria and 
were enrolled in the trial. Thereafter, 6.6% (10/152) of the 
participants were lost to follow-up, withdrew consent or 
migrated from study area by day 42.
Baseline characteristics
The baseline characteristics of enrolled study partici-
pants are summarized in Table  1. The median duration 
on ART was 2 years and almost two-thirds of the partici-
pants had a normal body mass index. Although over 80% 
of the participants reported fever at presentation, only a 
small proportion (7.9% [12/152]) were clinically febrile. 
Fig. 1 Trial profile and flow chart of participants. Trial profile and flow chart of malaria‑HIV co‑infected participants enrolled into in Zambia who 
were on efavirenz‑based antiretroviral therapy and were treated for malaria with artemether–lumefantrine
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Generally, the study population had a low median para-
site density with only one-third having baseline parasite 
density exceeding 2000 per μL. Nearly 45% of the partici-
pants had CD4 cell count < 350 cell/cu mm. Only 34.9% 
(53/152) reported taking cotrimoxazole prophylaxis.
Treatment dosage and tolerability
The daily median (range) dosages of artemether and 
lumefantrine administered to participants were 3.2  mg/
kg (2.3–4.6) and 19.2 mg/kg (13.5–27.4), respectively. The 
dosages were well tolerated: only one participant vomited 
following intake of AL on first day of treatment and was 
re-dosed. No participant was withdrawn from the study 
due to persistent vomiting.
Treatment efficacy
As shown in Table 2, there were no cases of ETF or LCF. 
There were 25 cases of late parasitological failure by day 
42 of follow-up (3 on day 28, 9 on day 35 and 13 on day 
42). Seventeen of the 25 cases of late parasitological fail-
ure had parasite genotyping results available. All 17 cases 
were confirmed as reinfections using PCR.
In the analysis of complete case records, excluding 
the 8 participants with missing PCR sample by day 42, 
the PCR-adjusted day-42 ACPR was 100% in both the 
ITT and PP populations. Additional file 1 illustrates the 
adjusted estimate of the proportion that experienced 
treatment success by day 42 in the ITT population.
The PCR-unadjusted day-42 ACPR, in the ITT popu-
lation was 83.6% (95% CI 76.7–88.7%) and 82.4% (95% 
CI 75.1–87.9%) in the PP population (Table  2). Addi-
tional file  2 shows the unadjusted estimate of the pro-
portion that experienced treatment failure by day 42 in 
the ITT population. The majority of the treatment fail-
ures occurred between days 35 and 42 (9 and 13 cases, 
respectively).
Sensitivity analyses performed for patients with una-
vailable malaria parasitological outcomes (due to lost 
to follow-up, missed day 42 visit or missing thick smear 
slides) showed that when cases with missing day-42 
PCR samples were treated as re-infections (scenario 1 
in Table 2), the PCR-adjusted ACPR was 100%, as in the 
primary analysis. If cases with missing PCR samples were 
treated as recrudescent infections (scenario 2 in Table 2), 
the PCR-adjusted day-42 ACPR was still well above 90%.
Parasite clearance time
Parasite clearance parameters were calculated in 57 and 
54 participants in the ITT and PP populations, respec-
tively, who had detectable parasitaemia at two or more 
post-dosing time points to allow determination of para-
site clearance slope. The median (range)  PC50 and the 
median (range)  PC90 were 5.7 (0.3–25.8) h and 13.8 (2.9–
32.9) h, respectively, in the ITT population and were 6.0 
(0.3–24.4) h and 13.1 (2.9–30.9) h, respectively, in the PP 
population.
Fever clearance
At baseline, 7.9% (12/152) of the participants were febrile 
(axillary temperature ≥ 37.5 °C). The median fever clear-
ance time (IQR) was 6 (6–12) h. None of the participants 
was febrile on days 1 and 2 of treatment.
Day‑7 plasma lumefantrine concentrations and other 
predictors of malaria recurrence by day 42
On day 7 of follow-up, blood samples were available from 
121 participants for quantification of lumefantrine con-
centrations. Among these, 36 participants had lumefan-
trine concentrations below the LLOQ (< 50 ng/mL). Since 
the proportion of participants with values below LLOQ 
was greater than 10%, the values below the LLOQ were 
handled in two ways as previously documented [29, 30]; 
in the first method only values above the LLOQ (n = 85) 
were used for analyses and in the second method, which 
was conducted as sensitivity analysis, values below LLOQ 
Table 1 Baseline characteristics of enrolled participants
Variable Artemether– 
lumefantrine +  
efavirenz‑based ART 
(N = 152)
Age in years, median (IQR) 40.4 (34–46.1)
Female (%) 101 (66.5)
Body mass index, kg/sq m, median (IQR) 19.5 (18.3–21.4)
WHO BMI classification, n (%)
 Underweight (< 18.5) 45 (29.6)
 Normal (18.5–24.9) 99 (65.1)
 Overweight (25.0–29.9) 5 (3.3)
 Obese (> 30) 3 (2.0)
Duration on ART in months, median (IQR) 24 (10.5–48)
Presenting symptoms, n (%)
 Fever 124 (81.6)
 Headache 119 (78.3)
 Fatigue 47 (30.9)
 Nausea 14 (9.2)
Axillary temperature at enrolment, median (IQR) 36.4 (36.0–36.7)
 Febrile, n (%) 12 (7.9)
Geometric mean parasite density, 95% CI 1108 (841–1463)
 Parasite density > 2000 parasites/µL, n (%) 53 (34.9)
 Parasite density > 10,000 parasites/µL, n (%) 19 (12.5)
Pre‑treatment haemoglobin concentration, g/dL, 
median (IQR)
11.3 (10.5–12.4)
Pre‑treatment CD4 cell count, median (IQR) 376 (248–511)
 CD4 cell count < 350, n (%) 67 (44.1)
Median (IQR) QTcF interval (ms) 393 (358–413)
Current use of cotrimoxazole prophylaxis, % (n) 53 (34.9)
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(n = 36) were included in the analyses after imputing the 
values to half the LLOQ (25 ng/mL).
In those with day-7 lumefantrine values above the 
LLOQ, the median (IQR) lumefantrine concentrations 
was 240 [143.2–370]  ng/mL. As shown in Fig.  2, the 
median (IQR) lumefantrine concentrations were not 
significantly different between participants who did not 
have malaria recurrence (246.8 [141.4–365.1]  ng/mL) 
and those who had malaria recurrence by day 42 (230.8 
[162.5–398.5] ng/mL, p = 0.779). In addition, the propor-
tion [95% CI] that attained day-7 plasma lumefantrine 
concentrations ≥ 200  ng/mL was not significantly dif-
ferent between those who experienced (69.2% [95% CI 
36.5–89.8]) and did not experience malaria recurrence 
by day 42 (58.3% [95% CI 46.4–69.3]; p = 0.460). None of 
the 36 participants who had day 7 lumefantrine concen-
trations below the LLOQ experienced malaria recurrence 
by day 42. Even after imputing data for these participants 
with lumefantrine values below the LLOQ, there was no 
difference in median day-7 lumefantrine concentration 
and the proportion that achieved lumefantrine concen-
trations ≥ 200 ng/mL between participants who had and 
did not have malaria recurrence by day 42.
In an exploratory analysis, none of the participant char-
acteristics predicted risk of malaria recurrence neither 
did they predict risk of re-infection among those with 
available PCR results by day 42 of follow-up (see Addi-
tional file 3).
Table 2 Efficacy outcomes, treatment success rates and   
sensitivity analyses by day 42 among the enrolled participants
ART antiretroviral therapy
a Scenario 1: indeterminate or unavailable PCR samples (as well as loss to 
follow-up in intention-to-treat population) treated as treatment success
b Scenario 2: indeterminate or unavailable PCR samples (as well as loss to 
follow-up in intention-to-treat population) treated as treatment failures
c Excluding 8 patients with indeterminate or unavailable PCR samples and 3 
patients with missing information on cotrimoxazole use
Variable Artemether lumefantrine + 
efavirenz‑based ART 
N = 152
Early treatment failure‑no. (%) 0
Late clinical failure‑no. (%) 0
Late parasitological failure‑no. (%) 25 (16.4)
 Recrudescence 0
 Reinfection 17 (11.2)
 PCR indeterminate or sample unavailable 8 (5.2)
Treatment success rate by day 42
 PCR‑unadjusted treatment success rate
  Intention‑to‑treat analysis
   Number of patients 152
   Rate‑% (95% CI) 83.6 (76.7–88.7)
  Per‑protocol analysis
   Number of patients 142
   Rate‑% (95% CI) 82.4 (75.1–87.9)
 PCR‑adjusted success rate excluding indeterminate or unavailable PCR 
samples
  Intention‑to‑treat analysis
   Number of patients 144
   Rate‑% (95% CI) 100
  Per‑protocol analysis
   Number of patients 134
   Rate‑% (95% CI) 100
Sensitivity analyses of treatment success rate by day 42
 PCR‑adjusted success rate (scenario  1a)
  Intention‑to‑treat analysis
   Number of patients 152
   Rate‑% (95% CI) 100
  Per‑protocol analysis
   Number of patients 142
   Rate‑% (95% CI) 100
 PCR‑adjusted success rate (scenario  2b)
  Intention‑to‑treat analysis
   Number of patients 152
   Rate‑% (95% CI) 94.7 (89.8–97.4)
  Per‑protocol analysis
   Number of patients 142
   Rate‑% (95% CI) 94.4 (89.1–97.2)
Treatment success rate by day 42 according to use of  cotrimoxazolec
 On cotrimoxazole prophylaxis in the intention‑to treat analysis
  Number of patients 53
  PCR‑adjusted rate‑% (95% CI) 100
 Not on cotrimoxazole prophylaxis in the intention‑to‑treat analysis
  Number of patients 88
  PCR‑adjusted rate‑% (95% CI) 100
Fig. 2 Day‑7 plasma lumefantrine concentration among 
malaria‑HIV‑co‑infected patients who had quantifiable 
concentrations above the lower limit of quantification (n = 85). 
Day‑7 plasma lumefantrine concentration in malaria‑HIV‑co‑infected 
patients who experienced malaria recurrence day 42 (n = 13) and 
those who did not experience recurrence day 42 (n = 72) in the 
intention‑to‑treat population. Individuals with unquantifiable or 
missing day‑7 lumefantrine concentrations (n = 30), a participant 
who withdrew consent before day 7 and individuals with 
lumefantrine values below the lower limit of quantification [< 50 ng/
mL] (n = 36) are excluded from the plot. Lumefantrine concentrations 
are given in ng/mL on a logarithmic scale. Red line is equivalent to 
200 ng/mL. Black line through the dot indicates median and the bar 
represents the interquartile range
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Serious adverse events and grade 3 or 4 treatment 
emergent adverse events
From enrolment to follow-up day 63, there was one SAE 
and two cases of grade 3 neutropaenia. The SAE was 
lobar pneumonia, confirmed on chest examination and 
radiography, that occurred on day 14 of follow-up in a 
31  years old female who had a baseline CD4 cell count 
of 164/μL and was not on cotrimoxazole prophylaxis. She 
was hospitalized and treated with intravenous antibiot-
ics. The lobar pneumonia resolved by day 28 of follow-up 
without sequela. The cases of grade 3 neutropaenia were 
in two male participants, 36 and 34  years old, who had 
baseline neutropaenia of grade 2 that worsened to grade 
3 by day 2 of treatment. In both cases, the neutropaenia 
resolved by day 7 of follow-up. None of these cases was 
judged to be probably related to intake of AL.
QT interval abnormalities
At baseline, only 3.9% (6/152) of participants had predose 
QTcF ≥ 450  ms. A change in QTcF interval of > 60  ms 
from baseline to day 2 occurred in 17.1% (26/152) of the 
patients (Table 3). The observed QTcF interval abnormal-
ities resolved by day 14 of follow-up. No cardiovascular 
abnormalities were detected in these individuals.
Haematological parameters
The mean (SD) haemoglobin concentrations remained 
unchanged from baseline to day 7 (efavirenz-ART group: 
11.3 to 11.2 g/dL (p = 0.592) but slightly increased from 
day 7 up to day 42, from 11.2 to 11.6  g/dL (p < 0.001). 
The median (IQR) CD4 cell count increased significantly 
from baseline to day 28, from 376 (248–511) to 458 (324–
624) (p < 0.001).
Discussion
The World Health Organization recommends the use 
of first-line anti-malarial drugs with cure rates of > 95% 
and changing anti-malarial drugs with cure rates of less 
than 90% [4]. This study was designed to assess whether 
AL achieves a day-42 PCR-adjusted malaria cure rate of 
90% in HIV-infected adults on efavirenz-based ART with 
uncomplicated falciparum malaria. AL achieved a day-
42 PCR-adjusted malaria cure rate of 100% in this sub-
population living in an area of moderate-to-high malaria 
transmission in northern Zambia. Even in the worst case 
scenario, where participants with missing PCR results by 
day 42 were considered as treatment failures, the PCR-
adjusted malaria cure rate was still > 94%. Additionally, 
AL achieved parasite clearance rates, similar to that in 
HIV-uninfected individuals [31–33]. Although there was 
no evidence of malaria recrudescence, at least 16% of the 
study participants had malaria recurrence by day 42, with 
the majority of the re-infections occurring between days 
35 and 42.
A few studies have previously examined the efficacy of 
AL in HIV-infected non-pregnant adults on efavirenz-
based ART. A Tanzanian study found that AL achieved 
a day-28 PCR-unadjusted cure rate of 82.5% in HIV-
malaria co-infected patients on efavirenz-based ART 
[11]. In this study, which had longer follow-up period, 
the day-42 PCR-unadjusted cure rate was 83.6% while the 
day-28 cure rate was 98.0%. It is difficult to make direct 
comparisons of findings from the two studies because, 
compared with the Tanzanian study participants, partici-
pants in this study had a higher median CD4 cell count, 
lower median baseline parasite density and lower median 
temperature at the time of presentation. Nevertheless, 
similar to the Tanzanian study, this study did not find any 
cases of early treatment failure suggesting a high efficacy 
of AL in clearing malaria parasites.
Previous pharmacokinetic studies have found lower 
lumefantrine and artemisinin concentrations in indi-
viduals on efavirenz-based ART than in ART-naïve 
individuals [8–10]. Although the incidence of malaria 
recurrence was high in this study, significant differ-
ences in median lumefantrine concentration were found 
Table 3 Median Fridericia corrected QT interval (QTcF) and  proportion with  abnormal ECG findings from  baseline 
to  last day of  dosing among  participants on  artemether–lumefantrine and  efavirenz-based antiretroviral therapy 
in the intention-to-treat population (N = 152)
IQR interquartile range, ECG electrocardiogram
Median (IQR) QTcF in msec Proportion with QTcF ≥ 450 ms Proportion with QTcF change > 60 ms 
from baseline to last day of dosing 
on day 2 (taken within 2 h of dosing)
Time of ECG test NA n (%) n (%)
 Day 0 393 (358–413) 6 (3.9) NA
 Day 1 392 (358–413) 6 (3.9) 19 (12.3)
 Day 2 384 (359–402) 1 (0.7) 26 (17.1)
 Follow‑up visit after day 2  
(day 7 or 14 of follow up)
392 (384–436) 0 NA
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between individuals with and without malaria recur-
rence, or those with confirmed re-infections, suggesting 
that lumefantrine concentrations had minimal impact on 
malaria recurrence, including re-infections. Previously, 
day-7 lumefantrine concentrations of ≥ 200 ng/mL have 
been shown to be a surrogate marker of overall lumefan-
trine exposure and they predict AL treatment success 
by days 28 or 42 of follow-up [34], with concentrations 
below this level being associated with increased risk of 
malaria recurrence (both recrudescence and reinfec-
tions). This study found no significant difference in the 
proportion that achieved day-7 lumefantrine concentra-
tions ≥ 200 ng/mL between participants who experienced 
malaria recurrence and those who did not experience 
malaria recurrence. These results contrast with those 
from a previous Tanzanian study [11] which found that 
malaria patients on ART who had recurrent parasitaemia 
by day 28, after treatment with AL, had lower median 
lumefantrine concentrations than those who remained 
aparasitaemic and that the proportion that achieved 
day-7 lumefantrine concentrations ≥ 280  ng/mL was 
higher in those who remained aparasitaemic. Reasons 
for the discrepancies are unclear. Nevertheless, partici-
pants in this study had a lower median day-7 lumefan-
trine concentration than the Tanzanian participants, 
suggesting that they were likely to have sub-therapeutic 
lumefantrine concentrations in the late post-treatment 
days 28–42 when most of the recurrent malaria infec-
tions occurred. The difference in day-7 lumefantrine 
concentrations in the two studies could be due to many 
factors, including genetic variations in CYP450 enzymes 
(CYP3A4 and CYP2B6) between the populations which 
metabolize ACT and efavirenz [35].
The finding of lack of evidence of an association 
between day-42 malaria recurrence and day-7 lumefan-
trine concentrations highlights that day-7 concentra-
tions are unlikely to be predictive of malaria recurrence 
beyond 28 days following malaria illness. This is similar 
to what has been previously shown in a pooled analysis of 
data from HIV-uninfected individuals treated for uncom-
plicated falciparum malaria [34].
In this study, AL was very well tolerated, as observed 
in studies involving HIV-negative individuals [32, 36, 37]. 
Study participants also experienced marked improve-
ment in CD4 count and haemoglobin levels following 
malaria treatment. Nevertheless, there were two cases 
of grade 3 neutropaenia that were judged as ‘unlikely 
related’ to AL. Also, 17.1% of the study participants had 
prolonged QTcF (> 60  ms) after AL treatment but none 
had an absoloute QTcF interval of > 500 ms or any clini-
cally detectable cardiac events. It is possible that the pro-
longed QTcF, which resolved by day 14 of follow-up, may 
have been due to fever resolution [38, 39] rather than 
lumefantrine toxicity. Taken together, these observations 
confirm the safety of AL in HIV-infected individuals on 
efavirenz-based ART which is in agreement with previ-
ous findings [10, 11] and are in line with WHO’s recom-
mendation on cardiac safety of ACT using the current 
standard treatment doses [40].
Understanding other factors, besides lumefantrine con-
centrations, associated with malaria recurrent malaria 
infections in HIV-co-infected individuals treated with 
AL can inform the optimal management strategies for 
malaria in this sub-population. This study did not find 
evidence of any significant association between patient 
characteristics, including use of cotrimoxazole prophy-
laxis or malaria parasite clearance rate, and malaria 
recurrence by day 42 (Additional file  3). In contrast, a 
previous pooled analysis of individual participant data 
from Asia and Africa found that baseline parasite den-
sity predicted risk of malaria recurrence among HIV-
uninfected individuals [41]. Participants in this study 
had relatively low initial parasitaemias, experienced a 
rapid parasite clearance and there were no cases of early 
treatment failure which may explain the lack of associa-
tion between baseline parasite density and malaria recur-
rence. Also, consistent with a previous Tanzanian study 
[11], this study found no significant association between 
baseline CD4 cell count and risk of malaria recurrence. 
Most of the study participants experienced improve-
ments in CD4 counts from baseline to post-treatment 
days 28 and 42, hence, baseline CD4 count was not a 
good marker of status of immunity in the post-treatment 
period when people were susceptible to malaria re-infec-
tions. This study was not designed or powered to iden-
tify predictors of malaria re-infections but future studies 
should do so.
The strengths of this study were that AL treatment 
doses were administered under direct observation, drug 
tolerability was closely monitored in hospital and the 
loss to follow-up rate was low. One limitation of the 
study was the missing PCR results in the few patients 
that experienced malaria recurrence. However, the miss-
ing data are unlikely to have significantly affected accu-
rate estimation of efficacy level of AL as highlighted in 
the sensitivity analyses. Another limitation was that the 
study cohort had a low median parasite density, hence 
the presence of non-malarial febrile illnesses cannot be 
ruled out. The high cure rates found in this study could 
have been due to the clearance of incidental low density 
parasitaemia which would have otherwise not required 
treatment. Nevertheless, AL still achieved rapid para-
site clearance among a sub-set of participants with high 
parasite densities and also achieved rapid fever clearance 
in patients who were febrile at baseline but received no 
additional treatment for other febrile illnesses. Due to 
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lack of pharmacogenetic data, this study did not investi-
gate the impact of polymorphisms in CYP2B6 enzymes 
on plasma efavirenz concentrations which in turn can 
result in higher plasma efavirenz concentrations avail-
able to induce the enzymes that metabolize lumefan-
trine (CYP3A4). Future studies should aim to assess this 
impact.
Conclusions
This study found that AL was safe and efficacious when 
used to treat uncomplicated falciparum malaria among 
HIV-infected adults on efavirenz-based ART which 
provides evidence for maintaining the same AL dos-
ing regimens used in HIV-uninfected individuals with 
uncomplicated malaria. Nevertheless, a higher than 
expected proportion of participants with malaria re-
infections was observed, which warrants the use of 
additional malaria prevention interventions in HIV-
infected adults on efavirenz-based ART.
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results at day 42 (n = 8) are excluded from the plot.
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